Androgen Receptor Expression and its Correlation with Other Risk Factors in Triple Negative Breast Cancers: a Report from Western Iran

  • Payandeh, Mehrdad (Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences) ;
  • Shazad, Babak (Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences) ;
  • Madani, Seyed-Hamid (Department of Pathology, School of Medicine, Kermanshah University of Medical Sciences) ;
  • Ramezani, Mazaher (Department of Pathology, School of Medicine, Kermanshah University of Medical Sciences) ;
  • Sadeghi, Masoud (Medical Biology Research Center, Kermanshah University of Medical Sciences)
  • Published : 2016.07.01


Background: Androgen receptors (ARs) are expressed in more than 70% of breast cancers (BCs) and have been implicated in BC pathogenesis. Some triple negative (TN)BC tumors express AR and may benefit from AR-targeted therapies. The aim of this study was to evaluate survival and the prevalence of AR expression and its correlation with other risk factors in triple negative BCs in women from Western Iran. Materials and Methods: In a retrospective study between 2009-2015, 41 patients with TNBC were referred to the Private Clinic of Oncology, Kermanshah city, Iran. ER, PR and AR-positive expression was defined as ${\geq}10%$ nuclear staining and also HER2 (2+), FISH was performed. Nuclear staining was considered representative for Ki67 and P53. The mean follow-up for the patients was 25 months. In this time, 5 patients died and 4 lost to follow-up were censored from survival analysis. Results: The mean age at diagnosis was 46.9 years (range, 24-71 years) and all patients were female. The OS rates for AR-positive and AR-negative patients were 90% and 85.1%, respectively, and the mean OS was 26.3 and 23.2 months. Therefore, there was no significant difference between the two groups (Hazard ratio: 0.580, 95% CI: 0.086-3.893, P=0.575). Conclusions: In TNBC patients, evaluation of AR status may provide additional information on prognosis and treatment. The results of studies showed that the prevalence AR expression may differ in the world and probably ethnicity can be an influencing factor.


  1. Anestis A, Karamouzis MV, Dalagiorgou G, Papavassiliou AG (2015). Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer? Cancer Treat Rev, 41, 547-53.
  2. Barton VN, D'Amato NC, Gordon MA, et al (2015). Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. Horm Cancer, 6, 206-13.
  3. Bryan RM, Mercer RJ, Bennett RC, et al (1984). Androgen receptors in breast cancer. Cancer, 54, 2436-40.<2436::AID-CNCR2820541121>3.0.CO;2-H
  4. Choi JE, Kang SH, Lee SJ, Bae YK (2015). Androgen receptor expression predicts decreased survival in early stage triplenegative breast cancer. Ann Surg Oncol, 22, 82-9.
  5. Gucalp A, Traina TA (2010). Triple-negative breast cancer: role of the androgen receptor. Cancer J, 16, 62-5.
  6. He J, Peng R, Yuan Z, et al (2012). Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol, 29, 406-10.
  7. Hu R, Dawood S, Holmes MD, et al (2011). Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res, 17, 1867-74.
  8. Lehmann BD, Bauer JA, Chen X, et al (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest, 121, 2750-67.
  9. Luo X, Shi YX, Li ZM, Jiang WQ (2010). Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer, 29, 585-90.
  10. McGhan LJ, McCullough AE, Protheroe CA, et al (2014). Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol, 21, 361-7.
  11. McNamara KM, Yoda T, Miki Y, et al (2015). Androgen receptor and enzymes in lymph node metastasis and cancer reoccurrence in triple-negative breast cancer. Int J Biol Markers, 30, 184-9.
  12. McNamara KM, Yoda T, Takagi K, et al (2013). Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol, 133, 66-76.
  13. Niemeier LA, Dabbs DJ, Beriwal S, et al (2010). Androgen receptor in breast cancer: expression in estrogen receptorpositive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol, 23, 205-12.
  14. Ogawa Y, Hai E, Matsumoto K, et al (2008). Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol, 13, 431-5.
  15. Park S, Koo J, Park HS, et al (2010). Expression of androgen receptors in primary breast cancer. Ann Oncol, 21, 488-92.
  16. Payandeh M, Sadeghi M, Sadeghi E, Aeinfar M (2015). Clinicopathology figures and long-term effects of tamoxifen plus radiation on survival of women with invasive ductal carcinoma and triple negative breast cancer. Asian Pac J Cancer Prev, 16, 4863-7.
  17. Payandeh M, Sadeghi M, Sadeghi E, Madani SH (2016a). Expression of p53 breast cancer in kurdish women in the west of Iran: a reverse correlation with lymph node metastasis. Asian Pac J Cancer Prev, 17, 1261-4.
  18. Payandeh M, Shahriari-Ahmadi A, Sadeghi M, Sadeghi E (2016b). Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status. Asian Pac J Cancer Prev, 17, 1015-8.
  19. Rakha EA, El-Sayed ME, Green AR, et al (2007). Prognostic markers in triple-negative breast cancer. Cancer, 109, 25-32.
  20. Shah PD, Gucalp A, Traina TA (2013). The role of the androgen receptor in triple-negative breast cancer. Womens Health (Lond Engl), 9, 351-60.
  21. Sullivan HC, Oprea-Ilies G, Adams AL, et al (2014). Triplenegative breast carcinoma in African American and Caucasian women: clinicopathology, immunomarkers, and outcome. Appl Immunohistochem Mol Morphol, 22, 17-23.
  22. Yu Q, Niu Y, Liu N, et al (2011). Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann Oncol, 22, 1288-94.